CEA and AFP expression in human hepatoma cells transfected with antisense IGF-I gene

Area of Science:

• Hepatology
• Molecular Biology
• Cancer Research

Background:

• Hepatocellular carcinoma (HCC) is a major global health concern.
• Insulin-like growth factor-I (IGF-I) plays a role in cell proliferation and survival.
• CEA and AFP are biomarkers associated with liver cancer progression.

Purpose of the Study:

• To investigate the effect of antisense IGF-I gene on CEA and AFP expression in HepG2 human hepatoma cells.
• To determine if modulating IGF-I can impact the expression of key liver cancer biomarkers.

Main Methods:

• HepG2 cells were transfected with antisense IGF-I gene using Lipofectin.
• Northern blot analysis confirmed antisense IGF-I RNA expression.
• Radioimmunoassay was used to quantify CEA and AFP levels in cell culture supernatant.

Main Results:

• Antisense IGF-I RNA was successfully expressed in transfected HepG2 cells.
• CEA levels were significantly reduced in transfected cells compared to controls (7.0 vs. 3.29 μg/L).
• AFP levels were also significantly reduced in transfected cells compared to controls (53.63 vs. 9.0 μg/L).

Conclusions:

• Antisense IGF-I gene can modulate the expression of CEA and AFP in human hepatoma cells.
• The findings suggest that antisense IGF-I gene therapy can partially suppress the malignant potential of HepG2 cells.
• Targeting IGF-I may offer a therapeutic strategy for managing hepatocellular carcinoma.